Telomir Pharmaceuticals Q4 2025 Earnings Wider Than Expected Loss Highlights ClinicalStage Challenges HCAT Q1 2026 Earnings Earnings Beat Sentiment but Stock Slips CAPS Q1 2026 Earnings EPS Misses Estimates as Losses Widen on Operational Challenges TS Q1 2026 Earnings EPS Surpasses Estimates But Stock Slips Amid Uncertain Revenue Outlook GDS Q1 2026 Earnings Massive EPS Beat Defies Expectations Despite Stock Dip VVOS Q1 2026 Earnings EPS Misses Estimates Amid Challenging Quarter